| abstract |
Referring to cyclic pyrazol-4-yl-heterocyclyl-carboxamide ether compounds of formula I, including stereoisomers, geometric isomers, tautomers and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl or pyrimidinyl, which are useful for inhibiting Pim kinase and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of formula I are disclosed for the in vitro, in situ and in vivo diagnosis, prevention or treatment of said disorders in mammalian cells, or associated pathological conditions. Preferred compounds are: 5-Amino-2- (2,6-difluorophenyl) -N- [5- (3,6-dihydro-2H-pyran-4-yl) -1-methyl-pyrazol-4-yl] thiazole -4-carboxamide; 5-Amino-2- (2,6-difluorophenyl) -N- [5- (3,4-dihydro-2H-pyran-6-yl) -1-methyl-pyrazol-4-yl] thiazole-4-carboxamide ; among others |